Why Is Blood Cancer Focused Arcellx Stock Trading Higher Today?
Portfolio Pulse from Vandana Singh
Arcellx Inc (NASDAQ: ACLX) announced new clinical data from its Phase 1 study of CART-ddBCMA in patients with relapsed or refractory multiple myeloma. The data shows a 100% overall response rate (ORR) in all patients. The stock is trading higher by 17.30% at $40.35.
November 02, 2023 | 4:39 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Arcellx's new clinical data shows promising results, leading to a rise in the company's stock price.
The announcement of positive clinical data from Arcellx's Phase 1 study has led to increased investor confidence, resulting in a rise in the company's stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100